Is CJC-1295 with GHRP-2 legal in the United States?

A 10 mg vial split evenly between a GHRH analogue and a ghrelin-receptor agonist. The pairing of those two drug classes has genuine human data, including a study in which combining them drove more growth hormone than either alone, but that work used different agents, given intravenously or by pump, in a clinic. No study has tested this vial.

This is the oldest rationale in the growth hormone corner of the peptide market: hit the pituitary from two directions at once. A GHRH analogue raises the size of a pulse, a ghrelin-receptor agonist triggers one and blunts somatostatin, and the two together do more than either.

Mechanism: Two receptors, one axis. The GHRH analogue binds the GHRH receptor on pituitary somatotrophs and increases the amplitude of a growth hormone pulse.

Regulatory history: Not approved. Neither component is an approved medicine in the United States, and the combination has never been evaluated.

Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.

The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for CJC-1295 with GHRP-2 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.